Investment

Revel Pharmaceuticals’ seed round for anti-aging drugs

Top Yale lab spawns new company focused on development of glucosepane-cleaving drugs. San Francisco based biotech start-up Revel Pharmaceuticals has announced itself to the...

Evolution 2.0 prize: The $10 million question

Major new prize announced to help identify how cells intentionally self-organise and communicate; George Church part of judging panel. The origin of life is often...

Longevity stocks: Stay private longer?

Going public as a Longevity stock is all about good timing and good clinical results: Some stand-out performers have experienced a volatile year. The world’s...

NeoGenomics acquires Human Longevity’s oncology tech

Acquisition of Human Longevity’s oncology division for $37m demonstrates both the opportunities and challenges for Longevity investing. On Friday, NeoGenomics announced that it had agreed...

Meet the Startup: Megilla – online storytelling

Easy to use Megilla platform is fundraising to scale-up its service to help older people share (and preserve) their life stories. Following on from last...

It’s all in the numbers; small sets of numbers

AI start-up NetraMark targets $3 million seed round while identifying that an exciting repurposing candidate has potential for indication expansion into Longevity. “I won’t tell you...

Longevity start-ups: 10 to watch in 2020

CNBC, a US television business news channel and website compiles a list of 100 of the most-promising venture-backed start-ups: Upstart100 With our Longevity focus firmly...

AgeX expects promising Longevity future

In its end of year letter to shareholders, AgeX Therapeutics sees a bright future for the Longevity market. Longevity.Technology: The days when aging was considered...

Longevity stocks: Go public with caution

SENS chief warns Longevity companies on perils of floating too soon. There is no doubt that the Longevity market is starting to take off. But...

AI innovators prefer autonomy to big pharma

AI drug discovery is hot; researchers expect it to reach US$20 billion in the next five years. Advances in AI see it is being used...

Washington’s Innovation in Longevity Summit

Conference to explore the global innovation opportunity in the Longevity market. Next week, the second Washington Innovation in Longevity Summit will be held in the...

Project 21 well on track

SENS Foundation business model evolves to focus on spin-outs. At the recent Longevity Forum in London, one of the keynote sessions was delivered by Dr...

Exclusive: Interview with US presidential candidate

Zoltan Istvan to challenge Trump in 2020; solving Longevity is at the top of his agenda. Last week, the transhumanist activist Zoltan Istvan announced his...

ZINC VC: On a mission to transform aging

Latest Zinc cohort addresses the quality of later life. London-based Zinc is forging a new way to solve the most important societal problems faced by...

Out of stealth and probing the dark side of DNA

Ervaxx CEO looks to raise new funding in 2020 to continue momentum on top of $17.5m Series A. Earlier this month, we reported on UK...

Longevity Week London: Key quotes and articles

Last week was a big turning point in Longevity: In key centres of academic and scientific endeavour the key players in Longevity aligned. The three intense...

SENS’ Underdog launches novel CVD treatment

SENS Research Foundation launches Underdog - a new therapeutic approach to cardiovascular disease (CVD). According to the World Health Organisation (WHO), cardiovascular diseases is the...

Longevity Forum 2019 and the 150 year life

Leaders in the Longevity sector gather for annual Forum, with the message that people could soon be living up to 150 years. It’s the third...

First Longevity AI Consortium launched at King’s

UK launch at King's College of AI Longevity Hub has bold plans for 2020 and beyond. Kings College London was home to a landmark event...

Small rooms, big opportunities

Thoughts from the floor of the Investing in the Age of Longevity conference. There’s something I love about being in a small conference room discussing...

Latest articles

VC enters Longevity market with K4Connect deal

We talk with VC investor Forte Ventures about its first foray into AgeTech, COVID-19 and the Longevity investment opportunity. Longevity agetech company K4Connect has announced...

Challenging the one drug/one disease model

A new paper supports the targeting of aging processes, rather than just one disease, to improve Longevity outcomes. Multimorbidity is a challenge for Longevity; defined...

Robotics and AI combine for new therapeutics discovery

Insilico Medicine and Arctoris announce robotics/AI partnership to focus on COVID-19 inhibitors that could have wide-reaching benefits for Longevity. Two companies have joined forces in...

The results are in: sharing our Longevity investment survey

There is rapidly-increasing activity in both the research and the investment communities that focus on Longevity; this survey gets into the details. The global Longevity...